Understanding the specific functional consequence of KCNH2 mutations (haploinsufficiency vs dominant-negative) allows for better risk stratification in long QT syndrome Type 2.
DN KCNH2 variants linked to higher arrhythmic risk than HI in LQT2; extends observational data for refined stratification but requires prospective validation.
No abstract yet. The journal hasn't published one we can show.
No takes yet. Share an insight, caveat, or question.
Lia Crotti (2023) conducted a review in Long QT syndrome Type 2. KCNH2 gene mutations (haploinsufficiency vs dominant-negative effect) vs. Wild-type (WT) was evaluated on QT interval corrected for heart rate (QTc) and arrhythmic risk.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: